BioLineRx (BLRX) BL-8040 Phase 1 Study Met All Safety and Efficacy Endpoints
Tweet Send to a Friend
BioLineRx Ltd. (NASDAQ: BLRX) announced today successful top-line results from the Phase 1 safety and efficacy study of its lead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
